Literature DB >> 12100454

National surveillance of dialysis-associated diseases in the United States, 2000.

Jerome I Tokars1, Mark Frank, Miriam J Alter, Matthew J Arduino.   

Abstract

In December 2000, all U.S. dialysis centers were surveyed regarding selected patient care practices and dialysis-associated diseases. The results were compared with similar surveys conducted in previous years. During 1997-2000, the percentage of patients vaccinated against hepatitis B virus infection increased from 47% to 58% and the percentage of staff vaccinated increased from 87% to 88%. In 2000, an estimated 64% of patients were vaccinated for influenza and 27% for pneumococcal pneumonia. In 2000, routine testing for antibody to hepatitis C virus (anti-HCV) was performed on staff at 40% of centers and on patients at 58% of centers; anti-HCV was found in 1.7% of staff and 8.4% of patients. During 1995-2000, the percentage of patients who received dialysis through central catheters increased from 13% to 24%; this trend is worrisome because infections and antimicrobial use are higher in patients receiving dialysis through catheters. However, during the same period the percentage of patients receiving dialysis through fistulas increased from 22% to 28%. In 2000, 25% of catheters were used for new patients awaiting an implanted access, 28% for established patients with a failed access awaiting a new implanted access, 41% as an access of last resort, and 6% for other reasons, including patient preference. The percentage of centers reporting one or more patients infected or colonized with vancomycin-resistant enterococcus (VRE) increased from 11.5% in 1995 to 32.7% in 2000.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12100454     DOI: 10.1046/j.1525-139x.2002.00051.x

Source DB:  PubMed          Journal:  Semin Dial        ISSN: 0894-0959            Impact factor:   3.455


  13 in total

1.  Profile of hepatitis B virus, hepatitis C virus, hepatitis d virus and human immunodeficiency virus infections in hemodialysis patients of a tertiary care hospital in uttarakhand.

Authors:  Garima Mittal; Pratima Gupta; Bhaskar Thakuria; Gulshan K Mukhiya; Manish Mittal
Journal:  J Clin Exp Hepatol       Date:  2013-02-09

2.  Pegylated-interferon alpha 2a treatment for chronic hepatitis C in patients on chronic haemodialysis.

Authors:  Ioan Sporea; Alina Popescu; Roxana Sirli; Ovidiu Golea; Camelia Totolici; Mirela Danila; Corina Vernic
Journal:  World J Gastroenterol       Date:  2006-07-14       Impact factor: 5.742

3.  Hepatitis C virus and its renal manifestations: a review and update.

Authors:  Nyan Latt; Nada Alachkar; Ahmet Gurakar
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-07

Review 4.  How to manage HIV-infected patients with chronic kidney disease in the HAART era.

Authors:  Minoru Ando; Ken Tsuchiya; Kosaku Nitta
Journal:  Clin Exp Nephrol       Date:  2012-06       Impact factor: 2.801

Review 5.  Management of chronic hepatitis C.

Authors:  V Lo Re; J R Kostman
Journal:  Postgrad Med J       Date:  2005-06       Impact factor: 2.401

6.  A review of evolving dialysis catheter technologies.

Authors:  Martha-Grace Knuttinen; Sonia Bobra; Julian Hardman; Ron C Gaba; James T Bui; Charles A Owens
Journal:  Semin Intervent Radiol       Date:  2009-06       Impact factor: 1.513

7.  Early steps to kidney transplantation among persons with HIV and end-stage renal disease in ESRD network 6.

Authors:  Ruth O Adekunle; Aneesh K Mehta; Zhengsheng Wang; Rachel E Patzer; Rebecca Zhang
Journal:  Transpl Infect Dis       Date:  2021-12-14       Impact factor: 2.228

Review 8.  Managing occupational risks for hepatitis C transmission in the health care setting.

Authors:  David K Henderson
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

Review 9.  Antiretroviral therapy : pharmacokinetic considerations in patients with renal or hepatic impairment.

Authors:  Sarah M McCabe; Qing Ma; Judianne C Slish; Linda M Catanzaro; Neha Sheth; Robert DiCenzo; Gene D Morse
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

10.  Efficacy and safety of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C.

Authors:  Celal Ayaz; Mustafa Kemal Celen; Ugur Nedim Yuce; Mehmet Faruk Geyik
Journal:  World J Gastroenterol       Date:  2008-01-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.